Overview

* Cingulate ( CING ) Q3 net loss of $7.3 mln missed analyst expectations

* R&D expenses rose 99.5% due to NDA submission costs for CTx-1301

* FDA accepted NDA for CTx-1301 with PDUFA date of May 2026

Outlook

* Company anticipates needing $7 mln additional capital before May 2026 PDUFA date

* Cingulate ( CING ) plans potential commercialization of CTx-1301 in 2026

* Cingulate ( CING ) has commercial supply agreement with Bend Bio Sciences for CTx-1301

Result Drivers

* R&D EXPENSES - Increased due to NDA submission costs for CTx-1301 and preparation for manufacturing validation batches

* G&A EXPENSES - Rise attributed to personnel costs and commercial preparation for CTx-1301 launch

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Miss -$7.30 -$3.82

Income mln mln (5

Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Cingulate Inc ( CING ) is $20.00, about 81% above its November 12 closing price of $3.80

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)